Overview

Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
An open-label, single institutional phase II trial of losartan in patients with primary and metastatic brain tumors with an individual stepped-wedge, randomized, assessor-blinded, dose-finding design on three indications.
Phase:
Phase 2
Details
Lead Sponsor:
Kyrre Eeg Emblem
Treatments:
Losartan